Drug Trial Radar · NCT07146191
RE104 Radiolabeled Mass Balance (hAME) Study
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Aug 19, 2025
Primary completion
Oct 2, 2025
Study completion Oct 2, 2025
Sponsor
- Lead sponsor
- Reunion Neuroscience IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of \[14C\]-RE104.
Conditions
- Healthy Participant Study
Interventions
2-[14C]-RE104 for InjectionDrug
Single, subcutaneous dose of 2-\[14C\]-RE104 for Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total excreted radioactivity (Ae)Time frame: Through 168 hours postdose
- Cumulative recovery of total excreted radioactivity (CUM Ae)Time frame: Through 168 hours postdose
- Area under the concentration-time curve (AUC) for RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
- Maximum observed concentration (Cmax) for RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
- Time to reach Cmax (Tmax) for RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
- Terminal half-life (t1/2) of RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
- Apparent terminal elimination half-life (λz) for RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
- Mean residence time (MRT)Time frame: Through 168 hours postdose
- Apparent total body clearance (CL/F) for RE104Time frame: Through 168 hours postdose
- Apparent volume of distribution during the terminal phase (Vz/F) for RE104Time frame: Through 168 hours postdose
- Total metabolite profiling with description of relevant PK parameters and structural identification of major metabolites present in all matricesTime frame: Through 168 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Inc.
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.